A practical reference on CAS Registry Number: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-16 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
=== Classic === Classic MSUD is the most common type of MSUD. It also has the earliest onset and is presented with the most severe symptoms. Symptoms can be seen from within 7–10 days of birth. The maple syrup odor to the earwax is apparent around 12 hours after birth. The sweet-smelling urine is presented around a week after birth when protein metabolism has accelerated. Some other signs that may be seen are poor feeding, vomiting, irritability, lethargy, apnea, seizures, acidosis, and encephalopathy. Infants with classic MSUD will display subtle symptoms within the first 24–48 hours. Subtle symptoms include poor feeding, either bottle or breast, lethargy, and irritability. The infant will then experience increased focal neurologic signs. These neurologic signs include athetosis, hypertonia, spasticity, and opisthotonus that lead to convulsions and coma. If MSUD is left untreated, central neurologic function and respiratory failure will occur and lead to death. Although MSUD can be stabilized, there are still threats of metabolic decompensation and loss of bone mass that can lead to osteoporosis, pancreatitis, and intracranial hypertension. Additional signs and symptoms that can be associated with classic MSUD include intellectual limitation and behavioral issues.
Reismanis was an information technology consultant at Accenture and intended to keep ModDB his hobby, but he left the firm to found DesuraNET as the website's hosting company, citing the expense of running the website and his recollection of IGN's 2006 attempt to acquire it. ModDB was integrated into DesuraNET's Desura, which was a digital distribution service that focused on indie games. The service opened in April 2010 as a competitor to Valve's Steam.
=== Discovery of GLP-2 actions leading to Short Bowel Syndrome treatments === In 1996, Drucker also discovered the first biological actions for GLP-2, demonstrating that it augmented crypt cell proliferation and expansion of the mucosal epithelium in the small bowel of mice and rats. He subsequently identified and characterized a DPP-4-resistant molecule, teduglutide, that was ultimately developed and approved for the treatment of short bowel syndrome in adults and children, a disorder in which fluids are poorly absorbed after resection of the small intestine.
== Additional functions == The ILEA had its own schools broadcasting service, the Educational Television Service, based in the former Tennyson Secondary School, Thackeray Road, SW8. The television centre had two functional television studios, a training studio, a master control and sound and vision mixing suites. At one stage this was believed to be the largest closed-circuit television system in the world. The first transmission took place on 16 September 1969 and the Television Service ran until 1977. When the Post Office, whose cabling was used for the distribution, wanted to withdraw from its contract in the late 1970s, the programming was transferred to VHS tapes and the CCTV network closed down. The Cockpit Theatre, Marylebone (also known at the Cockpit Youth and Arts Centre), in Gateforth Street, London, NW8, was built for the ILEA on the edge of the Lisson Green estate in 1969–70. It was designed as a Theatre in the round by Edward Mendelsohn. The ILEA created the first Theatre in Education company to be entirely housed within a local education authority. It employed seven actor-teachers and a stage manager and focused its work on secondary schools and Further Education. As well as traditional T.I.E. the Cockpit team used the approach to develop shows analysing set texts. When ILEA was abolished in 1990, ownership of the theatre transferred to the London Borough of Westminster. The ILEA had a planetarium, based at Wandsworth School. It was opened by the Astronomer Royal Sir Richard Woolley on 19 May 1966.
Sources: en.wikipedia.org
==== Government and state enterprises budget deficits ==== The year 2023 ended with a primary deficit of 230 billion reais, the second worst in history, behind only 2020, the year of the COVID-19 pandemic. According to Haddad, the result was increased, in part, by the decision to immediately pay the stock of court orders not paid during the Jair Bolsonaro Government, amounting to 92 billion Reals. Later, in 2024, According to the Central Bank of Brazil, federal state-owned enterprises recorded major losses during that year, totalling around 6.7 billion reais, the largest deficit in 23 years.
=== Batten disease === Milasen is a novel individualized therapeutic agent that was designed and approved by the FDA for the treatment of Batten disease. This therapy serves as an example of personalized medicine. In 2019, a report was published detailing the development of milasen, an antisense oligonucleotide drug for Batten disease, under an expanded-access investigational clinical protocol authorized by the Food and Drug Administration (FDA). Milasen "itself remains an investigational drug, and it is not suited for the treatment of other patients with Batten's disease" because it was customized for a single patient's specific mutation. However it is an example of individualized genomic medicine therapeutical intervention.
The fifth season of the American television drama series Scandal was ordered on May 7, 2015, by ABC, and began airing on September 24, 2015, in the United States on ABC. The season was produced by ABC Studios, in association with ShondaLand Production Company; the showrunner being Shonda Rhimes. The season continues the story of Olivia Pope's crisis management firm, Olivia Pope & Associates, and its staff, as well as staff at the White House in Washington, D.C. Season five has eleven series regulars, all returning from the previous season, out of which six are part of the original cast of eight regulars from the first season and three new regulars were added. The season will continue to air in the Thursday 9:00 pm timeslot, the same as the previous season as it was moved to make room for ShondaLand Production Company's new TV series, How to Get Away with Murder. On March 3, 2016, ABC announced that Scandal was renewed for a sixth season.
=== History === The Local Government Act 1888 reformed English local government by creating administrative counties, county boroughs, and elected county councils and county borough councils to govern them. County boroughs largely consisted of those settlements with a population over 50,000, and administrative counties covered smaller towns and rural areas. The three ridings of Yorkshire were reconstituted as the administrative counties of County of York, East Riding, County of York, North Riding, and County of York, West Riding. Within what would later become West Yorkshire, Bradford, Halifax, Huddersfield, and Leeds were made county boroughs. The Local Government Act 1972, which came into effect in 1974, reformed English local government again. It introduced metropolitan counties, which covered the largest urban areas, and non-metropolitan counties elsewhere. The metropolitan county of West Yorkshire was created from the central part of the West Riding and divided into five metropolitan boroughs. The provision of local government services was divided between West Yorkshire County Council and the district councils of the five boroughs. In Local Government Act 1985, which came into effect the following year, abolished the county council and transferred many of its powers and responsibilities the borough councils. It also created or allowed to be created joint bodies, notably the West Yorkshire Passenger Transport Executive, in which all the borough councils participated.
Recognition of its prevalence and consequences has led to governments and non-government organizations promoting vitamin A fortification of foods and creating programs that administer large bolus-size oral doses of vitamin A to young children every four to six months. In 2008, the World Health Organization estimated that vitamin A supplementation over a decade in 40 countries averted 1.25 million deaths due to vitamin A deficiency. A Cochrane review reported that vitamin A supplementation is associated with a clinically meaningful reduction in morbidity and mortality in children ages six month to five years of age. All-cause mortality was reduced by 14%, and incidence of diarrhea by 12%. However, a Cochrane review by the same group concluded there was insufficient evidence to recommend blanket vitamin A supplementation for infants one to six months of age, as it did not reduce infant mortality or morbidity.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.